Browse MICAL2

Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00307 Calponin homology (CH) domain
PF01494 FAD binding domain
PF00412 LIM domain
Function

Nuclear monooxygenase that promotes depolymerization of F-actin by mediating oxidation of specific methionine residues on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization. In the absence of actin, it also functions as a NADPH oxidase producing H(2)O(2) (By similarity). Acts as a key regulator of the SRF signaling pathway elicited by nerve growth factor and serum: mediates oxidation and subsequent depolymerization of nuclear actin, leading to increase MKL1/MRTF-A presence in the nucleus and promote SRF:MKL1/MRTF-A-dependent gene transcription. Does not activate SRF:MKL1/MRTF-A through RhoA.

> Gene Ontology
 
Biological Process GO:0001947 heart looping
GO:0003007 heart morphogenesis
GO:0003143 embryonic heart tube morphogenesis
GO:0006790 sulfur compound metabolic process
GO:0007015 actin filament organization
GO:0007368 determination of left/right symmetry
GO:0007389 pattern specification process
GO:0007507 heart development
GO:0008154 actin polymerization or depolymerization
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0010735 positive regulation of transcription via serum response element binding
GO:0019417 sulfur oxidation
GO:0030042 actin filament depolymerization
GO:0032984 macromolecular complex disassembly
GO:0035050 embryonic heart tube development
GO:0035239 tube morphogenesis
GO:0043241 protein complex disassembly
GO:0043624 cellular protein complex disassembly
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0051261 protein depolymerization
GO:0060562 epithelial tube morphogenesis
GO:0061371 determination of heart left/right asymmetry
Molecular Function GO:0003779 actin binding
GO:0004497 monooxygenase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016709 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen
GO:0043914 NADPH:sulfur oxidoreductase activity
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050662 coenzyme binding
GO:0071949 FAD binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MICAL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MICAL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MICAL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.2330.0169
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7190.654
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.5890.0961
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3730.327
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6450.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0270.993
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3840.519
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7740.622
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0430.98
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.870.528
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0480.29
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2770.0197
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MICAL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.49.6-2.21
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.411.9-4.50.713
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MICAL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MICAL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MICAL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MICAL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MICAL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MICAL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMICAL2
Namemicrotubule associated monooxygenase, calponin and LIM domain containing 2
Aliases KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ......
Chromosomal Location11p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MICAL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.